Status:
TERMINATED
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Lead Sponsor:
Genaera Corporation
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or ...
Eligibility Criteria
Inclusion
- Adult subjects ≥ 50 years of age.
- minimally classic or active occult choroidal neovascularization associated with age-related macular degeneration in one or both eyes.
- baseline best corrected visual acuity score between 35 to 65 letters according to the Early Treatment of Diabetic Retinopathy Study protocol.
- central retinal thickness by optical coherence tomography of \> 250 microns.
- lesions \> 9 disc areas.
- \> 25% fibrosis in the lesion.
Exclusion
- Previous history of triamcinolone, bevacizumab, ranibizumab, or pegaptanib sodium injection therapy in the study eye.
- retinal or optic nerve disease.
- uncontrolled diabetes.
- ongoing malignancy.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00333476
Start Date
May 1 2006
Last Update
November 28 2007
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Florida Eye Microsurgical Institute
Boynton Beach, Florida, United States, 33426
2
Retina Health Center
Fort Meyers, Florida, United States, 33907
3
Bascom Palmer Eye Institute
Miami, Florida, United States, 33136
4
Midwest Eye Institute
Indianapolis, Indiana, United States, 46280